Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized Phase IV Study Comparing Enzalutamide Versus Flutamide in Castration-resistant Prostate Cancer (CRPC) Patients Who Have Failed Combined Androgen Blockade Therapy With Bicalutamide Plus Androgen Deprivation Therapy (ADT)

NCT02918968 is registered in ClinicalTrials.gov with Astellas Pharma Inc as lead sponsor.

NCT NCT02918968
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02918968 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized Phase IV Study Comparing Enzalutamide Versus Flutamide in Castration-resistant Prostate Cancer (CRPC) Patients Who Have Failed Combined Androgen Blockade Therapy With Bicalutamide Plus Androgen Deprivation Therapy (ADT)
Lead sponsor
Astellas Pharma Inc
Phase
Phase 4
Overall status
Completed
Start date
November 2, 2016
Completion date
March 27, 2020
Enrollment
206 (actual)
Sites
47

Conditions

As the registry lists them; a condition with its own page is linked.

prostate cancer